ACE-031 Side Effects & Safety
ACE-031 has a documented safety profile in research. Understanding potential effects helps researchers design better studies.
Side Effects & Safety Profile
Common Side Effects
- Nosebleeds (epistaxis) - most frequently reported adverse event
- Gum bleeding
- Telangiectasia (dilated small blood vessels visible on skin)
- Skin erythema (redness)
- Minor injection site reactions
🛑 Stop Use & Seek Medical Attention If:
- Recurrent or severe nosebleeds
- Development of new or worsening telangiectasia
- Unexplained bleeding from any site
- Signs of hereditary hemorrhagic telangiectasia-like syndrome
- Severe skin reactions or widespread erythema
Contraindications
- NEVER approved for human use - clinical development discontinued
- History of bleeding disorders or vascular malformations
- Concurrent anticoagulant or antiplatelet therapy
- Known hypersensitivity to Fc fusion proteins
- Pregnancy or breastfeeding
Research Monitoring Recommendations
- Document baseline values before initiation
- Track subjective effects daily during first 2 weeks
- Monitor objective markers per protocol schedule
- Discontinue if stop signs appear
Related Sections
- Overview: What Is ACE-031?
Deep Dives: Key Benefits | Mechanism of Action | Research Indications | Dosing Protocols | Interactions & Stacking | What to Expect Timeline | FAQ | References & Studies | Quality Checklist
Product: ACE-031 — ≥98% (HPLC verified) · COA available · 1mg
Disclaimer: This compound is supplied for qualified research and laboratory purposes only. Not for human consumption, therapeutic use, or any application outside controlled research environments.
RaysunPeptide — Southeast Asia-based peptide manufacturer supplying research-grade compounds with HPLC/MS verification and Certificates of Analysis. B2B and qualified research applications.